Company Name
Shanghai Jinhe Bio-Pharmaceutical Co.,Ltd.
Year of Establishment
2002
Enterprise Size
100 to 149
Annual Turnover(USD)
500,000 to 999,999
Company Introduction
About us
Shanghai Jinhe Bio-Pharmaceutical Co., Ltd. (Abrr. “Jinhe”) , founded in March 2002, is a pharmaceutical enterprise dedicated to R&D, manufacturing and marketing anti-cancer APIs and their intermediates. Based on the R&D achievement of Fudan University, we began to undertake the international business of processing Paclitaxel API. After years of effort, we successfully developed Paclitaxel, Docetaxel, Irinotecan, Etoposide etc, from natural extracting anti-cancer products into material source anti-cancer APIs. In recent years, we developed new APIs, such as Cabazitaxel, Palonosetron hydrochloride etc. In 2012, we cooperated with Shanghai Zhongxi Sunve Pharmaceutical Co.,Ltd, (Abrr. “Sunve”) became a member of Shanghai Pharmaceuticals Holding Co.,Ltd. (Abrr. “SPH”). Since then, we targeted ourselves as the production base of SPH on oncology products. In 2015, we and Shanghai Huayu Chinese Herbs Co., Ltd. (Abrr. “Huayu”) both subsidiaries of SPH, reorganized Dali Zhonggu Yew Biological Co., Ltd. (Abrr. “Zhonggu Biological”) by way of investment in cash. This move indicates that SPH will further integrate its oncology drug industry chain and build its advantage in APIs. In January 2017, we achieved GMP certificate on Bulk Drug (Paclitaxel, Docetaxel). We are always committed to be a competitive and responsible company in global
Main Competitive Advantages
Brandname,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Buyers´ Specifications Accepted,Small Orders Accepted,Reputation,Quality Service,
Website
http://BIOTAXU.COM
Other Competitive Advantages
Patents and Copyright
A Synthetic method of Docetaxel;
Patent Number: ZL 2006 1 0116735.6;
Issue Date: 30 July, 2008;
A method of Extracting and Purifying 10- Deacetyl Baccatin III;
Patent Number: ZL 03 1 29635.1;
Issue Date: 18 May, 2005;</title><div style=position:
Milestone
Jinhe was established in March 2002. Based on the R&D achievement of FUDAN university, at the beginning it launched the international business of processing Paclitaxel API. After several years of development, we has been emerging as the largest processor on Taxus biomass in China. Afterwards, we successfully developed Docetaxel Anhydrous, Irinotecan HCl Trihydrate, Etoposide and other products, developing Anti-cancer products from nature extracting to semi-synthetical Anti-cancer products.